ADARx Prices $446.3 Million Nasdaq IPO, Extending Biotech's Run

ADARx Pharmaceuticals priced a $446.3 million Nasdaq IPO, one of the largest biotech debuts this cycle and the latest sign that the life-sciences listing window has reopened.